Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis

Abstract

The 2021 National report from IBD UK included responses from over 10 000 patients with inflammatory bowel disease, over 70% of whom reported having at least one flare in the last 12 months. As the first-line treatment for patients with mild and moderate ulcerative colitis, the action and delivery mechanisms of mesalazine are crucial for successful management of the disease. The choice of the most appropriate formulation of mesalazine and securing patient concordance and adherence to treatment remains a challenge for healthcare professionals. This article details the outcome of a roundtable discussion involving a group of gastroenterology consultants and specialist nurses which considered the importance of ensuring that patients have individualised mesalazine therapy before escalation to other treatments and gives recommendations for the management of patients with mild or moderate ulcerative colitis.

Formulation of Mesalamine-Loaded Rectal Mucoadhesive Pellets for the Treatment of Inflammatory Bowel Disease Using 32full Factorial Design

“…Mesalamine (MSL) is the first-line choice in the treatment of mild-tomoderate UC [5,6]. It has multiple anti-inflammatory actions that include inhibiting leukotrienes and Interleukin-1 production, lessening mucosal inflammation by acting on mucosal colonic epithelial cells, and acting as a free radical scavenger [7].…”